ABCB1 and neoplasm: The taxane class of anti-tubulin chemotherapeutics (e.g. paclitaxel, docetaxael) suffers from very similar disadvantages that includes acquired and intrinsic tumor resistance [120,123,140,141] secondary to the over-expression of multidrug resistance proteins (e.g. P-glycoprotein) [110,144,145], hypersensitivity reactions [146-149], hematopoietic toxicity (dose limiting feature) [150-152], and cumulative neurotoxicity [133,134,153] which can all curtail administration of treatment protocols [154].